Featured Research

from universities, journals, and other organizations

Cancer Treatment Targets Tumor Blood Supply In Patients

Date:
March 5, 2007
Source:
Cornell University
Summary:
An antibody called J591 specifically targets an antigen found in high amounts on both prostate tumors and on blood vessels of all solid tumors, according to a study by researchers at NewYork-Presbyterian Hospital/Weill Cornell Medical Center.

These scans show kidney cancer that has metastasized in a patient's left brain. The J591 antibody labeled with a radioactive marker targeted and revealed the cancer. (Credit: Image courtesy of Cornell University)
Credit: Image courtesy of Cornell University

A clinical trial has for the first time proven that an antibody called J591 specifically targets an antigen found in high amounts on both prostate tumors and on blood vessels of all solid tumors, according to a study by medical researchers at NewYork-Presbyterian Hospital/Weill Cornell Medical Center in New York City.

Related Articles


Since the prostate-specific membrane antigen (PSMA) exists only on tumors and not other tissues, J591 armed with a drug or radiation offers a way to selectively target cancer while leaving healthy tissues unharmed, thereby resulting in very low levels of toxicity and fewer side effects for patients.

While the study, published in the Feb. 10 issue of the Journal of Clinical Oncology, was designed to prove that J591 could exclusively target tumors (it did not try to reduce tumor size), researchers now have a vehicle for selectively transporting drugs or a radioactive isotope to destroy the blood vessels that feed tumors, thereby cutting off the cancer's blood supply.

"This was a proof-of-principle study designed purely to confirm that we could successfully target tumor vasculature without targeting normal tissue," said the study's senior author, Dr. Neil H. Bander, a urological cancer specialist at the medical center and the Bernard and Josephine Chaus Professor of Urological Oncology at Weill Cornell Medical College. "Now that we have confirmed specific and accurate targeting, in subsequent studies we will arm the J591 antibody with drugs or radioactivity, and then we will assess tumor response. We are already using such armed antibodies in patients with prostate cancer and have been able to show significant anti-tumor activity."

The research team used a radioactive tracer, attached to the antibody, to follow J591's progress throughout the body. The trial involved 27 cancer patients with a wide range of solid tumors -- including kidney, bladder, lung, breast, colorectal, pancreatic and skin. All patients had widespread disease that had failed conventional treatments.

PSMA has been an attractive target for cancer drug development because it is not only present in high amounts in prostate cancers but it also is the only known molecular target that is present on tumor blood vessels but not on normal blood vessels.

Other researchers are developing drugs that indirectly starve tumors of blood by reducing the growth of new blood vessels. But, such therapies are less effective against more advanced tumors with established blood vessels. By directly targeting tumor blood vessels, however, J591 treatments could destroy the tumor's blood supply and shrink even advanced tumors.

"In the future, we envision a multipronged attack on the tumor -- for example, combining therapies aimed directly at the malignant cells, along with therapies to both directly kill the tumor's blood supply as well as prevent it from regrowing," Bander said.

This work was supported by the U.S. National Institutes of Health, U.S. Department of the Army, Cancer Research Institute, David H. Koch Foundation, Robert McCooey Cancer Research Fund, Laurent and Alberta Gerschel Foundation, Yablans Family Foundation and BZL Biologics Inc. Bander is a consultant to -- and owns stock in -- BZL Biologics, which has licensed the PSMA antibodies from Cornell.

Co-researchers, all medical doctors, include Matthew Milowsky, David Nanus, Lale Kostakoglu, Shankar Vallabhajosula and Stanley Goldsmith of NewYork-Presbyterian Hospital/Weill Cornell Medical Center and Jeffrey Ross and Christine Sheehan of Albany Medical Center.


Story Source:

The above story is based on materials provided by Cornell University. The original article was written by Krishna Ramanujan, Cornell Chronicle. Note: Materials may be edited for content and length.


Cite This Page:

Cornell University. "Cancer Treatment Targets Tumor Blood Supply In Patients." ScienceDaily. ScienceDaily, 5 March 2007. <www.sciencedaily.com/releases/2007/03/070302171325.htm>.
Cornell University. (2007, March 5). Cancer Treatment Targets Tumor Blood Supply In Patients. ScienceDaily. Retrieved October 24, 2014 from www.sciencedaily.com/releases/2007/03/070302171325.htm
Cornell University. "Cancer Treatment Targets Tumor Blood Supply In Patients." ScienceDaily. www.sciencedaily.com/releases/2007/03/070302171325.htm (accessed October 24, 2014).

Share This



More Health & Medicine News

Friday, October 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins